Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384 –390

With interest, we read the article by Bezin et  al. (1), where a case-control study was reported that demonstrated increased risk of thyroid cancer among users of glucagon-like peptide 1 receptor agonists (GLP-1 RAs).
Source: Diabetes Care - Category: Endocrinology Source Type: research